TY  - JOUR
AU  - DeTemple, Viola K
AU  - Kaatz, Martin
AU  - Stockfleth, Eggert
AU  - Scheel, Christina
AU  - Angela, Yenny
AU  - Gutzmer, Ralf
AU  - Leiter, Ulrike
AU  - Meier, Friedegund
AU  - Schadendorf, Dirk
AU  - Livingstone, Elisabeth
AU  - Gebhardt, Christoffer
AU  - von Wasielewski, Imke
AU  - Weichenthal, Michael
AU  - Mohr, Peter
AU  - Hassel, Jessica
AU  - Pföhler, Claudia
AU  - Simon, Jan Christoph
AU  - Jochims, Franziska
AU  - Terheyden, Patrick
AU  - Ulrich, Jens
AU  - Haferkamp, Sebastian
AU  - Drexler, Konstantin
AU  - Schilling, Bastian
AU  - Glutsch, Valerie
AU  - Heinzerling, Lucie
AU  - Berking, Carola
AU  - Ugurel, Selma
AU  - Tomsitz, Dirk
TI  - Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.
JO  - European journal of cancer
VL  - 225
SN  - 0959-8049
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2025-01334
SP  - 115590
PY  - 2025
AB  - The anti-PD1 antibody (PD1i) cemiplimab is approved as second-line treatment for locally advanced or metastatic basal cell carcinoma (BCC), resulting in an ORR of 20-30 
KW  - Basal cell carcinoma (Other)
KW  - Cemiplimab (Other)
KW  - Hedgehog inhibitor (Other)
KW  - Immune checkpoint inhibitor (Other)
KW  - Real world data (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40580809
DO  - DOI:10.1016/j.ejca.2025.115590
UR  - https://inrepo02.dkfz.de/record/302794
ER  -